CJC 1295 Peptide (No DAC) – Premium Research Peptide

What Is CJC 1295 Peptide (No DAC)?

CJC 1295 Peptide without DAC, also known as Mod GRF (1-29), is a synthetic analog of growth hormone-releasing hormone (GHRH) designed for research into the growth hormone axis. Unlike its DAC-conjugated counterpart, this version lacks the Drug Affinity Complex (DAC) moiety, resulting in a shorter half-life of approximately 30 minutes to 2 hours and a more pulsatile pharmacokinetic profile .

As a tetrasubstituted form of hGRF(1-29) with four amino acid substitutions that resist enzymatic degradation, CJC 1295 Peptide binds selectively to GHRH receptors on anterior pituitary somatotrophs, stimulating the synthesis and release of endogenous growth hormone . The no-DAC version is frequently studied alongside short-acting ghrelin receptor agonists like Ipamorelin due to their matching pulse timing .

Understanding the distinction between DAC and no-DAC versions is critical for research reproducibility. As noted by Peptide Advisors, the no-DAC variant has a 30-minute to 2-hour half-life and preserves a pulsatile pattern, making it the typical pairing partner for Ipamorelin . The DAC version, by contrast, extends the half-life to approximately 5.8 to 8.1 days, producing sustained GHRH receptor stimulation .

---

Product Specifications

---

Research Applications

Growth Hormone Axis Stimulation

CJC 1295 Peptide provides researchers with a tool for investigating GHRH receptor activation and downstream growth hormone signaling. A foundational animal study published in Endocrinology demonstrated that CJC-1295 showed a 4-fold increase in GH area under the curve over a 2-hour period compared with hGRF(1-29) . The no-DAC version preserves this receptor activity while maintaining a shorter, more pulsatile profile suitable for acute research protocols.

Pulsatile GH Secretion Studies

The short half-life of CJC 1295 Peptide supports research into natural pulsatile GH secretion patterns. Clinical research published in the Journal of Clinical Endocrinology and Metabolism has evaluated the pharmacokinetics and pharmacodynamics of CJC-1295 in healthy adults, establishing foundational data for GHRH analog research . The no-DAC version more closely mimics the body’s natural GH pulses compared to the sustained elevation produced by the DAC version .

Synergistic Research with Ghrelin Agonists

CJC 1295 Peptide is frequently studied in combination with Ipamorelin, a selective ghrelin receptor agonist. Research indicates that GHRH analogs and ghrelin mimetics activate distinct but complementary pathways, producing synergistic GH release . The no-DAC form is the typical pairing partner for Ipamorelin because their pulse timing matches .

Metabolic and Body Composition Research

Preclinical research involving CJC 1295 Peptide typically investigates IGF-1 tracking as the primary downstream effector of pulsatile GH release. Studies have shown that CJC-1295 stimulates IGF-1 secretion, with mean IGF-1 levels remaining above baseline for extended periods after administration . This makes the peptide valuable for research into metabolism, body composition, and tissue repair mechanisms.

---

Quality and Purity

Each batch of CJC 1295 Peptide undergoes rigorous quality control testing to ensure:

• ≥99% purity verified by HPLC

• Correct molecular weight confirmed by mass spectrometry

• Consistent amino acid sequence validated by peptide mapping

Certificates of Analysis (COA) are available upon request, providing full transparency for research applications. Molecular weight confirmation on the COA is essential for verifying the correct version, as labeling conventions for CJC-1295 are not standardized across suppliers .

---

Frequently Asked Questions

What is CJC 1295 Peptide (No DAC)?

CJC 1295 Peptide (No DAC), also known as Mod GRF (1-29), is a synthetic GHRH analog with a shorter half-life of approximately 30 minutes to 2 hours. It is used as a research tool to study pulsatile growth hormone secretion and GHRH receptor activation .

How does CJC 1295 Peptide differ from the DAC version?

The DAC version contains a Drug Affinity Complex that binds to albumin, extending its half-life to approximately 5.8 to 8.1 days. The no-DAC version lacks this modification, resulting in a shorter half-life of 30 minutes to 2 hours and a more pulsatile pharmacokinetic profile .

What is the molecular weight of CJC 1295 Peptide?

CJC 1295 Peptide (No DAC) has a molecular weight of approximately 3,367 Da. Confirming molecular weight against the COA is the only reliable way to verify which version is in a vial .

What purity level can I expect?

Our CJC 1295 Peptide is provided at ≥99% purity, verified by HPLC.

How should CJC 1295 Peptide be stored?

CJC 1295 Peptide should be stored at -20°C for long-term stability. Lyophilised powder should be reconstituted according to standard laboratory protocols.

Is CJC 1295 Peptide FDA-approved?

No. CJC 1295 Peptide is a research peptide supplied for in-vitro laboratory use only. As of May 2026, neither CJC-1295 nor Ipamorelin is FDA-approved for any clinical use, and both were removed from Category 2 of the interim 503A bulks list in September 2024 .

---

References

• PubMed: Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor – Identification of CJC-1295 as a long-lasting GRF analog

• PubMed: Prolonged stimulation of GH and IGF-I secretion by CJC-1295 – Teichman 2006 foundational human pharmacokinetic study

• PubMed: Netnography of Female Use of the Synthetic Growth Hormone CJC-1295 – Patterns of use and research context

• Peptide Advisors: CJC-1295 + Ipamorelin Stack Guide – Regulatory status, mechanism, and research context

• Ubie Health: CJC-1295 DAC vs No DAC Medical Reality – Half-life comparison and dosing frequency analysis

• Bertin Bioreagent: CJC-1295 Product Data – Peptide sequence and GHRH analog classification

---

Conclusion

CJC 1295 Peptide (No DAC) is a short-acting GHRH analog for researchers investigating pulsatile growth hormone secretion, GHRH receptor activation, and downstream IGF-1 dynamics. With its 29-amino-acid sequence and approximately 30-minute half-life, this peptide enables studies that require a pharmacokinetic profile closer to natural GH pulsatility than the sustained elevation produced by DAC-conjugated versions .

For researchers requiring a reliable, high-purity GHRH analog for growth hormone research, CJC 1295 Peptide provides a well-characterized and precise research tool. Molecular weight confirmation via COA is essential for verifying the correct version .

---

Ready to Advance Your Research?

Order premium CJC 1295 Peptide for your research today. Contact our team for COA requests or technical inquiries.

Shop CJC 1295 Peptide Now

Contact Our Research Team